Document is current
Any future updates will be listed below
-
Authors
Palmer, Carter R.
Song, Jinghui https://orcid.org/0000-0003-2225-7977
Yang, Bing
Chen, Chien-Ju
Diep, Dinh
Conklin, Kimberly
Plongthongkum, Nongluk
Indralingam, Hannah S.
Liu, Christine S. https://orcid.org/0000-0002-1239-4612
Kurtz, Joshua https://orcid.org/0000-0002-8208-8813
Hu, Qiwen
Ransom, Linnea
Shahnaee, Anis
Hiniker, Annie
Hodge, Rebecca D. https://orcid.org/0000-0002-5784-9668
Dirk Keene, C. https://orcid.org/0000-0002-5291-1469
Lein, Ed https://orcid.org/0000-0001-9012-6552
Kharchenko, Peter
Zemke, Nathan R.
Chun, Jerold https://orcid.org/0000-0003-3964-0921
Ren, Bing
Zhang, Kun https://orcid.org/0000-0002-7596-5224
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (U01MH114828)
- License Information
-
More Information
Article History
Received: 8 July 2025
Accepted: 30 January 2026
First Online: 21 February 2026
Competing interests
: B.R. is a co-founder of Epigenome Technologies, and has equity in Arima Genomics. J.C. has an employment relationship with Neurocrine Biosciences Inc., a company that may potentially benefit from the research results. Dr. Chun’s relationship with Neurocrine Biosciences, Inc. has been reviewed and approved by Sanford Burnham Prebys Medical Discovery Institute in accordance with its Conflict of Interest Policies. The remaining authors declare no competing interests.
